Inside This Issue  by unknown
APRIL 10, 2012
VOLUME 59, NO. 15
JOURNAL of the AMERICAN COLLEGE of CARDIOLOGY
Inside This Issue
FOCUS ISSUE: TRANSCATHETER
CARDIOVASCULAR THERAPEUTICSSTATE-OF-THE-ART PAPER1337The Role of Endothelial Shear Stress in Stent Restenosis and ThrombosisKonstantinos C. Koskinas, Yiannis S. Chatzizisis, Antonios P. Antoniadis, George D. Giannoglou
Local hemodynamic factors, endothelial shear stress (ESS) in particular, may affect the
formation, progression, and heterogeneity of atherosclerotic plaque. Increasing evidence
suggests that ESS may also contribute to stent restenosis and thrombosis. In this review,
Koskinas and colleagues present in vivo and mechanistic evidence associating ESS with the
localization and progression of neointimal hyperplasia and in-stent clotting. Clinical studies
have associated stent design features with the risk of restenosis and computational simulations
have linked specific stent geometry and positioning characteristics with the post-stenting
hemodynamic milieu. Understanding the pathophysiologic role of ESS in restenosis and
thrombosis might lead to improved stent designs and deployment configurations which
reduce the potential for late lumen loss and thrombotic obstruction.INTERVENTIONAL CARDIOLOGY1350Similar Outcomes in “Real World” Patients With Zotarolimus- and Everolimus- StentsClemens von Birgelen, Mounir W. Z. Basalus, Kenneth Tandjung, K. Gert van Houwelingen,
Martin G. Stoel, J. (Hans) W. Louwerenburg, Gerard C. M. Linssen, Salah A. M. Saïd,
Miep A. W. J. Kleijne, Hanim Sen, Marije M. Löwik, Job van der Palen, Patrick M. J. Verhorst,
Frits H. A. F. de Man
The TWENTE trial compared the safety and efficacy of zotarolimus-eluting stents (ZES)
with everolimus-eluting stents (EES) with a prospective, randomized design in “real-world”
patients. Acute coronary syndromes were present in one-half of the enrollees and at least 1
off-label feature in three-quarters of patients. Target vessel failure (TVF) rates were the same
at 8.2% and 8.1%. There were no significant between-group differences in any of the
components of TVF with low and similar rates of stent thrombosis. These results show that
ZES are noninferior to EES for treating “real-world” patients with complex lesions and
“off-label” indications.(continued on page A-31)
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1362Novel Bioabsorbable Polymer-Coated,
Everolimus-Eluting Stent Shows Promising ResultsIan T. Meredith, Stefan Verheye, Christophe L. Dubois, Joseph Dens, Jean Fajadet, Didier Carrié,
Simon Walsh, Keith G. Oldroyd, Olivier Varenne, Seif El-Jack, Raul Moreno, Anita A. Joshi,
Dominic J. Allocco, Keith D. Dawkins
The EVOLVE trial compared the safety and efficacy of 2 dose formulations of SYNERGY,
a novel bioabsorbable polymer everolimus-eluting stent (EES) (Boston Scientific Corp.,
Natick, Massachusetts) to the durable polymer PROMUS Element EES (Boston Scientific
Corp.). The SYNERGY stent platform delivers everolimus from an ultrathin bioabsorbable
polymer which degrades into carbon dioxide and water within 4 months. Nearly 400 subjects
with de novo lesions were randomly assigned to PROMUS Element, SYNERGY, or
SYNERGY (half dose). There were no statistically significant differences in the primary
clinical endpoint of 30-day target lesion failure (TLF). The new stents were also noninferior
for the secondary endpoint of 6-month, in-stent late loss, or clinical event rates.INTERVENTIONAL CARDIOLOGY1371Polymer-Free Amphilimus-Eluting Stent Superior to Paclitaxel-Eluting StentDidier Carrié, Jacques Berland, Stefan Verheye, Karl Eugen Hauptmann, Mathias Vrolix, Roberto Violini,
Alain Dibie, Sergio Berti, Eric Maupas, David Antoniucci, Joachim Schofer
The Cre8 stent (CID, Saluggia, Italy) uses a cobalt-chromium alloy, coated by (0.3 m)
assive carbon layer, with a biodegradable mixture of long-chain fatty acids slowly releasing
irolimus. Carrie and colleagues randomized 323 subjects with de novo coronary lesions to the
olymer-free (PF) amphilimus-eluting stents or permanent-polymer (PP) paclitaxel-eluting
tents. At 6 months, in-stent late lumen loss was significantly lower in the subjects
andomized to Cre8 with no difference in clinical endpoints up to 12 months. This small
tudy suggests improved outcomes with a novel polymer-free stent design.INTERVENTIONAL CARDIOLOGY1377Drug-Coated Balloon Superior to Plain Balloon Angioplasty for DES RestenosisHarald Rittger, Johannes Brachmann, Anil-M. Sinha, Matthias Waliszewski, Marc Ohlow, Andreas Brugger,
Holger Thiele, Ralf Birkemeyer, Volkhard Kurowski, Ole-A. Breithardt, Martin Schmidt, Stefan Zimmermann,
Sandra Lonke, Moritz von Cranach, The-Vinh Nguyen, Werner G. Daniel, Jochen Wöhrle
Drug-coated balloon angioplasty was associated with favorable results for treatment of bare-
metal stent restenosis but paclitaxel-coated balloon angioplasty has not been adequately
evaluated for the treatment of drug-eluting stent (DES) restenosis. In this prospective,
randomized trial, Rittger and colleagues randomly assigned 110 patients with DES restenosis
to paclitaxel-coated balloon angioplasty or uncoated balloon angioplasty. The paclitaxel-coated
balloon was superior with a late loss of 0.43 mm compared to 1.03 mm with accompanying
significant reductions in the restenosis rate and the composite clinical endpoint. Paclitaxel-
coated balloon angioplasty is superior to plain balloon angioplasty for treating DES restenosis.(continued on page A-32)
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1383Proximal Balloon Occlusion Better Than Filter for
Preventing Cerebral Embolization During Carotid Artery StentingKlaudija Bijuklic, Andreas Wandler, Fadia Hazizi, Joachim Schofer
Proximal balloon occlusion during carotid artery stenting (CAS) reverses flow in the internal
carotid so that, theoretically, any embolic material released by the stenting procedure can be
aspirated from just distal to the balloon prior to restoring antegrade flow. Bijuklic and
colleagues compared the cerebral embolic load of filter versus proximal balloon protection in
62 consecutive patients. The primary endpoint, which was the incidence of new cerebral
ischemic lesions found on diffusion weighted magnetic resonance imaging, was significantly
lower with balloon occlusion. In this randomized trial of patients undergoing CAS, proximal
balloon occlusion significantly reduced the embolic load to the brain compared to filter
protection.Editorial Comment: Robert D. Safian p. 1390CORONARY DISEASE
1392New Index of Stenosis Severity Correlates
Closely With FFR Without Requiring Adenosine Infusion-6
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)Sayan Sen, Javier Escaned, Iqbal S. Malik, Ghada W. Mikhail, Rodney A. Foale, Rafael Mila, Jason Tarkin,
Ricardo Petraco, Christopher Broyd, Richard Jabbour, Amarjit Sethi, Christopher S. Baker, Micheal Bellamy,
Mahmud Al-Bustami, David Hackett, Masood Khan, David Lefroy, Kim H. Parker, Alun D. Hughes,
Darrel P. Francis, Carlo Di Mario, Jamil Mayet, Justin E. Davies
Determining the hemodynamic significance of a stenosis with fractional flow reserve (FFR)
requires that coronary resistance is stable and minimized which is achieved by administration
of the vasodilator adenosine. Sen and colleagues hypothesized that there is a time during
diastole when coronary resistance is minimal and the effects of the rebound wave are
minimized. Wave intensity analysis of cardiac pressure wire recordings identified a wave-free
period where intracoronary resistance is similar in variability and magnitude to that during
adenosine infusion. The resting distal to proximal pressure ratio during this period, the
instantaneous wave-free ratio (iFR), correlated closely with FFR with excellent diagnostic
efficiency. The iFR produces a measurement of stenosis severity comparable to FFR without
requiring adenosine infusion.Editorial Comment: Morton J. Kern p. 1403
